ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 10

An Overview to Myelofibrosis and Disease Risk

, , , ,

Panelists discuss myelofibrosis (MF) and its diagnostic workup, including how patients with primary MF present, the criteria required for diagnosis, and any additional biomarkers or criteria examined in practice.

EP. 1: Initial Treatment Strategies for Polycythemia Vera
EP. 2: Cytoreductive Therapy in PV Treatment Paradigm
EP. 3: JAK Inhibition in Polycythemia Vera: Treatment Updates
EP. 4: Interferon Therapy in PV
EP. 5: Safety Considerations for PV Therapy
EP. 6: Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence
EP. 7: Interferon Real- World Treatment Patterns in PV
EP. 8: Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
EP. 9: Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024
Now Viewing
EP. 10: An Overview to Myelofibrosis and Disease Risk
EP. 11: Treatment Goals for Myelofibrosis
EP. 12: Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials

Video content above is prompted by the following:

  • What outstanding updates in PV from ASH 2024 are noteworthy?
  • What do you see for the future of PV treatment?
  • What are the greatest unmet needs?
  • How are ongoing investigational therapies helping to address these unmet needs?
  • What clinical pearls can you share for community oncologists?